Results per Page:
¿Necesito otra vacuna de refuerzo contra el SRAS-CoV-2?
Del Dr. Bo Zhang y laboratorios colaboradores, División de Vacunas y Enfermedades Infecciosas
Barriers to adherence of 1-year surveillance colonoscopy for CRC patients
From the Issaka Lab, Public Health Sciences and Clinical Research Divisions
Successful long-term outcomes for unrelated bone marrow transplants
From the Deeg Lab, Clinical Research Division
First in-human HIV vaccine to induce virus-specific neutralizing antibodies
From the McElrath Lab, Vaccine and Infectious Disease and Clinical Research Divisions
Trazar la heterogeneidad de las células tumorales en el cáncer de próstata resistente a la castración
Del Laboratorio Haffner, Divisiones de Biología Humana e Investigación Clínica
Do I need another SARS-CoV-2 booster vaccine?
From Dr. Bo Zhang and collaborating labs, Vaccine & Infectious Disease Division
Mapping tumor cell heterogeneity in castrate-resistant prostate cancer
From the Haffner Lab, Human Biology and Clinical Research Divisions
El interruptor molecular para el exceso y la carencia de nutrientes tiene un mismo regulador
Del Laboratorio Rajan, División de Ciencias Básicas
Vaccine targets that accommodate evolving SARS-CoV-2 variants
From the Overbaugh Lab, Human Biology and Public Health Sciences Divisions
Molecular switch for nutrient surplus vs. deprivation have a common controller
From the Rajan Lab, Basic Sciences Division
El momento en que se administra la TAR para el VIH es más importante de lo que imaginábamos
De los grupos de los doctores Edlefsen y Frenkel, Consorcio Oncológico
Menopausal hormone therapy may lower the risk of colorectal cancer
From the Peters and Hsu Groups, Cancer Consortium & Public Health Sciences Division
Timing of ART administration for HIV is more important than we thought
From the Edlefsen and Frenkel Groups, Cancer Consortium
Sacituzumab govitecán para el cáncer de mama metastásico triple negativo
De la Dra. Sara Hurvitz, División de Investigación Clínica
Safety and feasibility approved for new therapy to treat relapsed hematologic malignancies
From the Bleakley Lab, Translational Science & Therapeutics Division
Cost-effective device trains immune cells to kill tumor cells
From the Matthias Stephan Lab, Translational Science & Therapeutics Division
Una dosis de bortezomib por semana es suficiente para tratar el mieloma múltiple
Del Dr. Rahul Banerjee, División de Investigación Clínica
Once-weekly bortezomib is enough to treat multiple myeloma
From Dr. Rahul Banerjee, Clinical Research Division
Sacituzumab govitecan for metastatic triple-negative breast cancer
From Dr. Sara Hurvitz, Clinical Research Division
La eficacia de la vacuna contra el virus SARS-CoV-2 en países de América Latina
Del Grupo Gilbert, Divisiones de Vacunas y Enfermedades Infecciosas y de Ciencias de la Salud Pública